title: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
abstract: BACKGROUND
  Mitoxantrone (MITO) is associated with dose-related cardiotoxicity when administered concomitantly with other cytotoxic agents with or without radiotherapy for leukemia and solid tumors.
  
  
  OBJECTIVE
  To review observed cardiotoxicity of single-agent MITO therapy for MS.
  
  
  METHODS
  Records of 1,378 patients from three clinical trials of MITO treatment for MS were reviewed for signs and symptoms of cardiac dysfunction and left ventricular ejection fraction (LVEF) results. Duration of follow-up was a median of 29 months (4,084 patient-years).
  
  
  RESULTS
  No patients experienced congestive heart failure (CHF) before treatment. Cumulative MITO doses ranged from 2 to 183 mg/m(2) (mean 60.5 mg/m(2), median 62.5 mg/m(2)), and 141 patients received >100 mg/m(2). Two of 1,378 patients experienced CHF after initiating MITO therapy. Of 1,378 patients, 779 completed baseline and scheduled follow-up LVEF testing. Baseline LVEF was >50% in all 779 patients. Seventeen of 779 patients had asymptomatic LVEF of <50% (incidence proportion = 2.18%, 95% CI = 1.28 to 3.47%). Although the incidence of asymptomatic LVEF of <50% was not significantly related to monthly versus 3-monthly therapy, duration of therapy, age, or gender, asymptomatic LVEF of <50% trended higher with a cumulative dose of >/=100 mg/m(2) (5.0%) than with <100 mg/m(2) (1.8%) (p = 0.06).
  
  
  CONCLUSIONS
  The observed incidence of CHF in patients with MS who received a mean cumulative dose of 60.5 mg/m(2) MITO was <0.20%. Continued monitoring of patients with MS who are receiving MITO is needed to determine whether the incidence of CHF increases with higher cumulative MITO doses and prolonged follow-up.
authors.affiliation: Immunex Corp., Seattle, WA 98101, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Ghalie
authors.forename: G
authors.initials: G
authors.lastname: Edan
authors.forename: M
authors.initials: M
authors.lastname: Laurent
authors.forename: E
authors.initials: E
authors.lastname: Mauch
authors.forename: S
authors.initials: S
authors.lastname: Eisenman
authors.forename: H P
authors.initials: HP
authors.lastname: Hartung
authors.forename: R E
authors.initials: RE
authors.lastname: Gonsette
authors.forename: M D
authors.initials: MD
authors.lastname: Butine
authors.forename: D E
authors.initials: DE
authors.lastname: Goodkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D004334:Drug Administration Schedule; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects*; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012189:Retrospective Studies; D012737:Sex Factors; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D008942:Mitoxantrone